Trial Profile
A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms BRILLIANCE
- Sponsors Janssen; Janssen Research & Development
- 01 Jan 2022 Results (n=131) of this post-hoc analysis published in the Acta Haematologica
- 21 Jun 2020 Results of post-hoc analysis assessing treatment pattern on survival in Chinese patients (n=131) presented at the 25th Congress of the European Haematology Association.
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.